Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade is currently the leading biologic for Crohn's disease, but Abbott/Eisai's Humira will soon become the first-choice among biologics.

Patient-level claims data indicate that Remicade currently captures a larger share of Crohn's disease patients on every line of therapy than Humira. However, 56 and 65 percent of surveyed gastroenterologists and primary care physicians say that, over the next two years, they will increase their use of Humira on the first and second lines of therapy, respectively. This shift will occur because Humira is easier to use--it can be self injected in the privacy of one's home versus having to go to the physician's office as is the case with Remicade which is administered intravenously. In addition, both gastroenterologists and primary care physicians say they will increase their use of Humira as a maintenance therapy.

According to interviewed experts, physicians are increasingly moving patients to biologics early in treatment.

"Moving up in lines of therapy means an expanded potential patient population for these agents," stated Michael Malecki, Ph.D., analyst at Decision Resources. "Because biologics are much more expensive than conventional agents, the trend of using them earlier in therapy will result in a net market expansion in terms of dollars."

The new report entitled Treatment Algorithms in Crohn's Disease also finds that oral 5-aminosalicylates will continue to be used in early lines of therapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's Lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to Lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyorin Seiyaku's Pentasa over the next two years.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

The reports can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst and are welcome to attend our upcoming webinar entitled Biologics Penetration of Early Lines of Therapy in Psoriasis, Crohn's and Rheumatoid Arthritis: Implications for Existing and Emerging Brands. The webinar will be held on Wednesday, November 19, 2008 at 10 a.m. EST. For more information, please contact Natalia Morales at 781.296.2691 or e-mail at nmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Natalia Morales                              Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   nmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
nmorales@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

The Pharmaceutical Industry and the Election - New Report Available for Free From Decision Resources

View Now